Purpose. The new lipoglycopeptide dalbavancin has only been approved for acute bacterial skin and skin structure infections. However, its alternative use as a catheter lock solution could facilitate the conservative management of catheterrelated bloodstream infection. Our objective was to assess the stability and activity of dalbavancin alone and in combination with heparin against methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE) biofilms. We also compared the results with those obtained with vancomycin alone and in combination with heparin.
INTRODUCTION
Dalbavancin is a new lipoglycopeptide that is highly active against Gram-positive bacteria. Owing to its pharmacokinetic and pharmacodynamic characteristics, it only needs to be administered as single IV doses every 7-14 days [1] [2] [3] [4] .
At present, dalbavancin is only approved for the treatment of soft tissue infections, although several studies have also demonstrated its efficacy for other infections, such as catheter-related bloodstream infections (CRBSIs) [5] [6] [7] [8] [9] [10] [11] [12] .
Catheter withdrawal followed by systemic antimicrobial therapy is the mainstay of the treatment of CRBSIs. However, conservative management of CRBSIs, especially in long-term tunnelled catheters that are difficult to replace, has been successful in several clinical studies [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] .
When the catheter cannot be removed, lock solutions based on antimicrobial agents with good biofilm penetration are indicated. The literature contains few data on the potential application of dalbavancin as a lock solution in catheters that must be retained and are colonized by Gram-positive microorganisms [25, 26] .
We used an in-vitro model to compare the activity of vancomycin and dalbavancin alone and in combination with heparin in reducing the activity of staphylococcal biofilms.
METHODS
The study was performed in the laboratory of the Department of Clinical Microbiology and Infectious Diseases at Gregorio Marañón Hospital, Madrid, Spain. Scanning electron microscopy (SEM) was performed at the Centro Nacional De Microscopía Electrónica, Universidad Complutense, Madrid, Spain.
We designed an in vitro static 96-well plate model ( Fig. 1 ) using a methicillin-resistant Staphylococcus aureus (MRSA) ATCC 43300, a methicillin-resistant Staphylococcus epidermidis (MRSE) ATCC 35984 and 2 comparators of clinical strains (1 MRSA and 1 MRSE) isolated from long-term catheters of patients with CRBSIs, which had previously been demonstrated to be high biofilm producers by crystal violet assay (absorbance !1.292) [27] . The clinical strains were identified using standard microbiological methods and MALDI-TOF, and the resistance profiles were determined using standard reference microbiological methods (microdilution). The results were expressed as a mixture of ATCC and clinical strains.
The recommended concentration of vancomycin as a lock solution is 5 mg ml À1 [28] . For dalbavancin, we decided to prepare a solution concentrated at 1000Â the minimal inhibitory concentration (as the guidelines recommend) for staphylococci (0.128 mg ml À1 ) [28] . As for locking periods of >2 h an anticoagulant must be added, we also tested the combination of each antibiotic with heparin 60IU (heparin sodium, 5000 IU 5 ml
À1
; Hospira Prod. Farm. y Hosp, S.L., Spain), as is the standard in our institution for lock therapy.
Heparin and dalbavancin activity assays were performed to test the viability of heparin and dalbavancin combined as a potential antibiotic lock solution over 7 days in a clinical practice setting.
Biofilm formation in 96-well plates Biofilm was formed as described by Peeters et al., with some modifications [29] . Briefly, a loopful of fresh culture (24 h) of each strain was inoculated in 20 ml of TSB (supplemented with glucose 1 % for S. epidermidis strains) and incubated at 37 C in an orbital shaker for 24 h. The inocula were then washed with PBS via three centrifuge-resuspension cycles, and the pellets were resuspended in 10 ml of TSB. These suspensions were adjusted to 0.5 McFarland turbidity using a turbidimeter, and 100 µl was inoculated on a 96-well plate. After 24 h of biofilm formation at 37 C, the plates were washed three times with PBS. Each strain was tested in triplicate, and positive and negative controls were included. From this point on, the wells were exposed to the respective treatments described below.
Dalbavancin and vancomycin solutions and treatment procedure Pure dalbavancin powder (MCE, Spain) was reconstituted in 100 % dimethyl sulfoxide. The media used for the ALT solution were cation-adjusted Mueller-Hinton broth and 0.002 % Tween. Two solutions of 0.128 mg ml À1 were prepared for testing alone and in combination with heparin 60 IU.
Vancomycin (Sigma-Aldrich Química, S.L.) was reconstituted and prepared in sterile water. Two solutions of 5 mg ml À1 were prepared for testing alone and in combination with heparin 60 IU.
After preparation, each solution was filtered using a 0.22 µm Millipore filter and stored at 4 C.
One hundred microlitres of each solution was added to the completely dry plates, which were incubated at 37 C for 24 h. Then, the plates were washed three times with PBS and dried at room temperature before the viability assays. Quantification of bacterial load and cell viability by colony-forming unit (c.f.u.) counts and confocal laser scanning microscopy (CLSM) Wells were vigorously scraped with 100 µl of PBS, and triplicates of the treatments and controls were mixed separately in a pool. Four 1 : 100 serial dilutions were performed, and two aliquots were obtained: a 100 µl aliquot of each dilution, which was plated on blood agar plates and incubated at 37 C for 24 h, and another aliquot, which was stained using the Live/Dead BacLight kit (Invitrogen, Barcelona, Spain) for 15 min in darkness.
Colonies of the plates were counted, and the percentage reduction in c.f.u. well À1 was calculated using equation 3. Colony counts were expressed on a logarithmic scale as the number of c.f.u. ml Cells were stained using 0.5 µl of SYTO 9 (stock 3.34 mM DMSO) and 0.5 µl of propidium iodide (stock 20 mM DMSO) in 20 µl of sample mounted on coverslips and imaged using CLSM in an inverted confocal fluorescence microscope (SPE, Leica Microsystems) equipped with ACS APO 10Â/0.30 and ACS APO 63Â/1.30 objectives. Samples were imaged using an ACS APO 63Â/1.30 objective. During imaging, SYTO 9 emits green fluorescence and is used to identify living micro-organisms with an intact membrane, whereas propidium iodide emits red fluorescence and stains dead bacteria with a damaged membrane.
We analysed three CLSM images of each sample (1500Â magnification). The images were quantified using FIJI software (National Institutes of Health, USA).
The percentage of live bacteria was calculated as the ratio between the number of live cells and the total number of cellsÂ100 (equation 4):
Analysis of biofilm structure by SEM SEM was only used to study the structure of the biofilm of the MRSA and MRSE ATCC strains. Biofilms were formed on 13 mm polystyrene discs for 24 h at 37 C in a 24-well plate and then incubated for 24 h at 37 C with 300 µl of each solution, as follows: dalbavancin 0.128 mg ml
, dalbavancin 0.128 mg ml À1 +heparin 60 IU, vancomycin 5 mg ml À1 and vancomycin 5 mg ml À1 +heparin 60 IU. The plates were then washed three times with PBS and dried at room temperature. SEM was performed after the wells had been fixed in 300 µl of 2 % glutaraldehyde, dehydrated in graded alcohol and sputter-coated with gold atoms (1500Â magnification).
Each strain was tested in triplicate, and positive and negative controls were included.
The structure of the treated and non-treated biofilms was visualized using SEM (JEOL-JSM 6400, Jeol, Tokyo, Japan).
Heparin activity assay
We performed an anti-Xa assay to analyse whether heparin activity could be altered when it was combined with dalbavancin during a 7-day period. The anti-Xa assay was an automated machine in which anti-Xa reagent (HemosIL Liquid Anti-Xa) was added and absorbance was measured at 405 nm. The results for heparin activity were reported as IU ml À1 . We used a 2 ml solution of dalbavancin (0.128 mg ml À1 )+heparin 60 IU over a 7-day incubation period at 37 C and compared the results with those obtained with a 2 ml control of heparin 60 IU in 5 % glucose solution. Both solutions were tested against 1 ml of a pool of plasma from patients with normal coagulation at days 0, 3, 5 and 7 of incubation. The median [interquartile range (IQR)] heparin concentrations (IU ml À1 ) obtained in the four anti-Xa assays were compared between the solutions. The experiments were performed in duplicate.
We considered that the viability of heparin was not altered when the heparin concentration (IU ml À1 ) in the solution based on dalbavancin and heparin did not exceed more than 25 % of the reference value of the control (heparin alone) throughout the experiment. The experiments were performed in duplicate.
Dalbavancin stability assay during 7-day incubation period with heparin We performed a metabolic activity assay using a solution of dalbavancin (0.128 mg ml À1 )+heparin 60 IU over a 7-day incubation period at 37 C and compared the results with those obtained with a solution of dalbavancin alone (0.128 mg ml
À1
). Both solutions were tested against 24 h biofilms of the MRSA and MRSE ATCC strains at days 1, 3, 5, and 7 of the incubation period. Metabolic activity was measured using the XTT assay, and median (IQR) absorbances obtained at 490 nm in the spectrophotometer were compared between both solutions.
We considered that the activity of dalbavancin was not altered when the reduction in metabolic activity in the dalbavancin+heparin solution was not below 15 % of the reference value of the control (dalbavancin alone) throughout the experiment.
Statistical analysis
The qualitative variables appear with their frequency distribution. The quantitative variables are summarized as the median (IQR). Normally distributed continuous variables were compared using the t-test, and non-normally distributed variables were compared using the Kruskal-Wallis test. The differences between groups were compared using the Mann-Whitney test with a Bonferroni correction. All of the statistical tests were two-tailed.
Statistical significance was set at P<0.05. The statistical analysis was performed using IBM SPSS Statistics for Windows, version 21.0 (IBM Corp, Armonk, New York, USA).
RESULTS
Comparison of dalbavancin and vancomycin solutions against MRSA We found statistically significant differences in the median (IQR) percentage reduction in metabolic activity (XTT) between dalbavancin+heparin and vancomycin+heparin: 90.0 % (70.4-92.9 %) versus 35.0 % (14.8-59.6 %), respectively (P=0.006) (Fig. 2a) . As for the reduction in biomass, dalbavancin+heparin tended to be more effective, although the difference was not statistically significant (38.1 versus 0.0, respectively: P=0.113). The median (IQR) reduction in c.f.u. counts and cell vability for dalbavancin+heparin and vancomycin+heparin were, respectively, as follows: 19.3 % (19.2 % -no p75 value obtained) versus 19.8 % (16.5 % -no p75 value obtained), P=0.439, and 45.9 % (34.2-57.5 %) versus 62.8 % (35.7 % -no p75 value obtained), P=0.517 (Fig. 2a) . The most representative images obtained with SEM for MRSA ATCC 43300 demonstrated that the values for the bacteria and the matrix were significantly lower after treatment with dalbavancin+heparin and vancomycin+hep-parin compared to those after treatment with the positive control (Fig. 3a) . We only detected significant differences between dalbavancin and vancomycin alone in terms of the median (IQR) percentage reduction in metabolic activity and biomass, respectively, as follows: 88.9 % (84.7-92.2 %) versus 39.3 % (3.6-56.5 %), P<0.001, and 42.3 % (21.7-50.1 %) versus 0.0 % (0.0-21.7 %), P=0.019.
A comparison of the results obtained with each antibiotic alone and in combination with heparin did not reveal statistically significant differences.
Comparison of dalbavancin and vancomycin solutions against MRSE
We only found statistically significant differences in the median (IQR) percentage reduction of metabolic activity between dalbavancin and vancomycin alone: 93.2 % (90.8-96.4 %) and 68.4 % (62.4-86.4 %), respectively (P=0.009) (Fig. 2b) . (Fig. 2b) .
The most representative images obtained with SEM for MRSE ATCC 35984 demonstrated that the values for the bacteria and the matrix were significantly lower after treatment with dalbavancin+heparin and vancomycin+heparin compared to after treatment with the the positive control (Fig. 3b) .
We did not find any statistically significant differences when we compared the results obtained with each antibiotic alone or in combination with heparin.
Heparin activity assay during the 7-day incubation period with dalbavancin The mean (SD) heparin concentration (IU ml À1 ) during the 7-day incubation period for the dalbavancin+heparin soluution and heparin alone was as follows: day 0, 3.8 (0.50) ver- (Fig. 4) . None of the concentrations of heparin in combination with dalbavancin during the 7-day incubation ) against biofilm from MRSA ATCC 43300. Samples were fixed in glutaraldehyde, dehydrated in graded alcohol and sputter-coated with gold atoms (1500Â magnification). A single representative image depicting the largest percentage of biofilm eradication is reported for each treatment. As is shown, the MRSA biofilm was eradicated to a slightly greater extent and the extracellular matrix was reduced when dalbavancin+heparin was used compared to vancomycin+heparin. (b) Scanning electron microscopy images of dalbavancin and vancomycin being used in combination with heparin (60 IU ml À1 ) against biofilms from MRSE ATCC 35984. Samples were fixed in glutaraldehyde, dehydrated in graded alcohol and sputter-coated with gold atoms (1500Â magnification). A single representative image depicting the largest percentage of biofilm eradication is reported for each treatment. As with the MRSA strains, the MRSE biofilm was eradicated to a slightly greater extent and the extracellularmatrix was reduced when using dalbavancin+heparin was used compared to vancomycin+heparin.
exceeded more than 25 % with respect to the reference values for heparin concentrations alone.
Dalbavancin stability assay during the 7-day incubation period with heparin Our results in Table 1 showed that the reduction in the metabolic activity of the MRSA and MRSE ATCC strain biofilms was not affected when the solution of dalbavancin and heparin was conserved for 7 days compared with the solution of dalbavancin alone.
DISCUSSION
Dalbavancin, a new lipoglycopeptide, shows good in vitro activity for most Gram-positive bacteria, while it also has an extremely long half-life [32] [33] [34] . Dalbavancin is increasingly accepted as an alternative in infections other than soft tissue infections [7, [10] [11] [12] [35] [36] [37] [38] [39] .
CRBSI is a major nosocomial problem whose management sometimes requires the catheter to be preserved. International guidelines recommend combining systemic antimicrobials with antibiotic lock therapy (ALT), and this approach is supported by several authors [28, [40] [41] [42] . The current guidelines recommend using vancomycin as the ALT in the management of CRBSIs caused by Grampositive micro-organisms. However, the success rates for catheter salvage during the treatment of CRBSIs vary widely [14-17, 21, 22, 26, 43-49] . Moreover, the regimen of administration of vancomycin and its associated adverse effects led us to look for alternative antibiotics with good anti-biofilm activity that can be used as an antibiotic lock solution. Such alternatives include dalbavancin, since it has the advantage of single-dose administration and 7-day catheter lock.
Based on previous studies showing the feasibility of antibiotic/heparin lock solutions with dwell times of up to 10 days, we confirmed that both heparin and dalbavancin maintained their effectiveness and stability in an antimicrobial lock solution over 7 days [50] [51] [52] . We could not even find statistically significant differences between dalbavancin/vancomycin and dalbavancin+heparin/vancomycin +heparin in the reduction of biofilm in the strains tested.
Our data show that the in vitro efficacy of dalbavancin reduced the metabolic activity of MRSA and MRSE biofilms compared with vancomycin. When dalbavancin and vancomycin were combined with heparin, dalbavancin also significantly reduced the metabolic activity of MRSA biofilms. Moreover, despite the absence of statistically significant differences in c.f.u. counts in MRSE, dalbavancin+heparin and vancomycin+heparin reduced the c.f.u. counts by 4 and 3 log 10 units, respectively. This finding was confirmed by SEM, as the values for the biofilm and the matrix were significantly reduced. For the remaining variables, dalbavancin +heparin showed no inferiority with respect to vancomycin for the MRSA or MRSE strains.
Only two in vitro studies have previously tested the activity of dalbavancin against staphylococci biofilms when used as an ALT. Meeker et al. demonstrated better activity for telavancin in terms of c.f.u. reduction in the USA300 MRSA than for dalbavancin. However, the authors used a 72 h exposure time and 160Â as the breakpoint of telavancin for both compounds, i.e. the dalbavancin concentration was 10 times lower than the dose we used (0.0192 mg ml À1 ) [26] . Therefore, no comparison can be made with our results, in which we used a concentration of 0.128 mg ml À1 for dalbavancin. Sevillano et al. also compared the c.f.u. counts using an in vitro model based on 48 h exposure of catheter segments to different concentrations of antimicrobials and showed that dalbavancin had the best results, even at a lower concentration (0.05 mg ml À1 ) [25] . However, they only tested the c.f.u. count reduction as a marker of cell viability, which is not exactly the same. In our study we not only analysed the c.f.u. count reduction, but also cell viability, using CLSM by staining cells with SYTO 9 and propidium iodide. They showed an approximately 60 % reduction of c.f.u. counts when the catheters were treated with dalbavancin (5 mg ml
À1
), compared to a 33 % reduction when the catheters were treated with vancomycin (5 mg ml À1 ), which was a greater difference than was seen in our results, mainly because the dalbavancin concentration was five times higher.
Compared to the previous studies, ours is the first in vitro study based on a static microtitre plate model to compare a series of variables with the aim of quantifying the reduction in MRSA and MRSE strain biofilms after 24 h treatment with dalbavancin (0.128 mg ml One of the limitations of our study was the fact that the stability of dalbavancin was not directly assessed using high-performance liquid chromatography. We measured its efficacy indirectly using the XTT assay to assess whether metabolic activity was reduced or not during the incubation period. We also found that the crystal violet assay was not appropriate for the assessment of the efficacy of these solutions, as it seemed that the antibiotic stained itself in the crystal violet assay, even though it also showed a statistically significant reduction in biomass in MRSA. Another limitation of the study was that, even if in vitro static models are the most commonly used methods to rapidly and easily test different treatments against biofilms, the results may not exactly represent what occurs in the clinical setting. It is also important to test the efficacy of dalbavancin as a catheter lock solution using a standard concentration (higher than 0.128 mg ml
) that can be prepared easily from the i.v vial that will be used in clinical practice. Moreover, we consider that the dalbavancin lock solution should be tested for a large collection of clinical strains and also in an animal model of CRBSI before use in a clinical setting. 
